Holy Stone Healthcare Co., Ltd. (TPEX:4194)

Market Cap	1.04B
Revenue (ttm)	47.51M
Net Income (ttm)	-139.59M
Shares Out	145.97M
EPS (ttm)	-0.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,939
Average Volume	48,451
Open	6.92
Previous Close	7.13
Day's Range	6.89 - 7.24
52-Week Range	5.32 - 12.65
Beta	0.72
RSI	41.96
Earnings Date	Mar 26, 2026

About Holy Stone Healthcare

Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid related therapeutic products. in Taiwan. The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. It also developing IBD98-M, which is in Phase IIa clinical trials for the treatment of ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4194

Financial Performance

In 2024, Holy Stone Healthcare's revenue was 118.77 million, a decrease of -49.86% compared to the previous year's 236.89 million. Losses were -183.49 million, -36.59% less than in 2023.